| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 7909-IL-010/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 1399-IL-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 8134-IL-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 1258-IL-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56541SS | |||
| Azide and BSA Free | NBP2-33223 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF1399-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB1399-SP | |||
| Carrier Free | MAB1399-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-27324SS | |||
| Azide and BSA Free | NBP2-80795 | |||
![N/A IL-17E/IL-25 [Biotin]](http://images.novusbio.com/fullsize2/DATA_IL17E_DY1399_ELISA_1641.jpg "N/A IL-17E/IL-25 [Biotin]")
![Western Blot: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Analysis of IL-17E using IL-17E monoclonal antibody. Mouse testis lysate probed with IL-17E antibody at 2 ug/mL.](http://images.novusbio.com/fullsize/IL-17E-IL-25-Antibody-68C1039-2-Western-Blot-NB100-56541-img0007.jpg "Western Blot: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Analysis of IL-17E using IL-17E monoclonal antibody. Mouse testis lysate probed with IL-17E antibody at 2 ug/mL.")
![Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - Immunohistochemistry (IHC) staining of IL-17E/IL-25 was performed in a tissue microarray consisting of 74 CRC tumor tissues and adjacent colon tissues (left). Statistical analysis of IL-17E/IL-25 staining in adjacent specimens and CRC specimens (right). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IL-17E-IL-25-Antibody-68C1039-2-BSA-Free-Immunohistochemistry-NB100-56541-img0008.jpg)
![Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Tissue section of mouse liver using IL17E/IL25 antibody clone 68C1039.2 at 1:150. The antibody generated a diffused cytoplasmic staining in the hepatocytes with a very strong signal in the sinusoidal endothelial cells.](http://images.novusbio.com/fullsize/IL-17E-IL-25-Antibody-68C1039-2-Immunohistochemistry-Paraffin-NB100-56541-img0004.jpg)
![Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Tissue section of mouse kidney using IL17E/IL25 antibody clone 68C1039.2 at 1:150. The antibody generated a diffused cytoplasmic staining in the tubular and ductal epithelia cells, and a strong positivity in the inter-tubular/ductal blood vessels.](http://images.novusbio.com/fullsize/IL-17E-IL-25-Antibody-68C1039-2-Immunohistochemistry-Paraffin-NB100-56541-img0005.jpg)
![Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Adrenal cortex, Human](http://images.novusbio.com/fullsize/IL-17E-IL-25-Antibody-68C1039-2-Immunohistochemistry-NB100-56541-img0006.jpg)
![Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p 6. The patients with CRC were divided into 2 groups according to the intra-tumor IL25 IHC-score: low group (n = 34), high group (n = 15). (E) Representative images of IL25 IHC staining from WT colon & AOM/DSS induced tumors on weeks 10 & 16 (down). Statistical analysis of IL25 staining in con colon, adjacent tissues, & AOM/DSS-induced CRC tissues (up). Data present as mean ± SEM; *p 6. The patients with CRC were divided into 2 groups according to the intra-tumor IL25 IHC-score: low group (n = 34), high group (n = 15). (E) Representative images of IL25 IHC staining from WT colon & AOM/DSS induced tumors on weeks 10 & 16 (down). Statistical analysis of IL25 staining in con colon, adjacent tissues, & AOM/DSS-induced CRC tissues (up). Data present as mean ± SEM; *p 6. The patients with CRC were divided into 2 groups according to the intra-tumor IL25 IHC-score: low group (n = 34), high group (n = 15). (E) Representative images of IL25 IHC staining from WT colon & AOM/DSS induced tumors on weeks 10 & 16 (down). Statistical analysis of IL25 staining in con colon, adjacent tissues, & AOM/DSS-induced CRC tissues (up). Data present as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56541_mouse-monoclonal-il-17e-il-25-antibody-68c1039-2-310202415533813.jpg)
![Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56541_mouse-monoclonal-il-17e-il-25-antibody-68c1039-2-310202415535127.jpg)
![Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56541_mouse-monoclonal-il-17e-il-25-antibody-68c1039-2-310202415535171.jpg)
![Immunocytochemistry/Immunofluorescence: IL-17E/IL-25 Antibody (RM0263-5J46) [NBP2-11677] - Immunofluorescence for IL25-positive cells (red), actin (green) and nuclei (blue) in lung tissue from control mice. The control mice had no experimental manipulation performed. C57BL/6 male mice (Jackson Laboratories, Bar Harbor, Me), 8 to 12 weeks old and weighing 20 to 30 g, were used in this study. Samples were imaged on a FluoView 1000 confocal scanning microscope (Olympus). Imaging conditions were maintained at identical settings within each antibody-labeling experiment with original gating performed using the negative control (no primary antibody). Image courtesy of Center for Biologic Imaging, The University of Pittsburgh](http://images.novusbio.com/fullsize/IL-17E-IL-25-Antibody-RM0263-5J46-Immunocytochemistry-Immunofluorescence-NBP2-11677-img0003.jpg "Immunocytochemistry/Immunofluorescence: IL-17E/IL-25 Antibody (RM0263-5J46) [NBP2-11677] - Immunofluorescence for IL25-positive cells (red), actin (green) and nuclei (blue) in lung tissue from control mice. The control mice had no experimental manipulation performed. C57BL/6 male mice (Jackson Laboratories, Bar Harbor, Me), 8 to 12 weeks old and weighing 20 to 30 g, were used in this study. Samples were imaged on a FluoView 1000 confocal scanning microscope (Olympus). Imaging conditions were maintained at identical settings within each antibody-labeling experiment with original gating performed using the negative control (no primary antibody). Image courtesy of Center for Biologic Imaging, The University of Pittsburgh")
![Western Blot: IL-17E/IL-25 Antibody (8B1) [NBP2-27324] - Analysis of IL17E in full-length recombinant protein using IL17E antibody at 0.5 ug/ml.](http://images.novusbio.com/fullsize/IL-17E-IL-25-Antibody-8B1-Western-Blot-NBP2-27324-img0004.jpg "Western Blot: IL-17E/IL-25 Antibody (8B1) [NBP2-27324] - Analysis of IL17E in full-length recombinant protein using IL17E antibody at 0.5 ug/ml.")
![Flow Cytometry: IL-17E/IL-25 Antibody (8B1) [NBP2-27324] - Intracellular analysis of IL-17E in PC3 cells using 1 ug of IL-17E antibody (green histogram represents isotype control antibody this antibody , red represents IL-17E antibody. this antibody was used for this test, and an anti-mouse IgG PE conjugated secondary antibody this antibody .](http://images.novusbio.com/fullsize/IL-17E-IL-25-Antibody-8B1-Flow-Cytometry-NBP2-27324-img0003.jpg)